Therapeutische Nanobodies gegen SARS-CoV-2

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1868-6249

Extent: Online-Ressource

Language: Deutsch

Notes: online resource.

Bibliographic citation: Therapeutische Nanobodies gegen SARS-CoV-2 ; volume:28 ; number:1 ; day:13 ; month:2 ; year:2022 ; pages:39-42 ; date:2.2022
Biospektrum ; 28, Heft 1 (13.2.2022), 39-42, 2.2022

Keyword: SARS-CoV-2
Deutschland

Creator: Güttler, Thomas
Dobbelstein, Matthias
Görlich, Dirk

Contributor: SpringerLink (Online service)

DOI: 10.1007/s12268-022-1684-y

URN: urn:nbn:de:101:1-2022051820434746774423

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:22 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Güttler, Thomas
Dobbelstein, Matthias
Görlich, Dirk
SpringerLink (Online service)

Other Objects (12)

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2

Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses

NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies

Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies

Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2

Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses

NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies

Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies

Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2

Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses

NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies

Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies

Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Therapeutische Nanobodies gegen SARS-CoV-2

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2

Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses

NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies

Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies

Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2

Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses

NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies

Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies

Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2

Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses

NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies

Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies

Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

Related objects

Reset password